NLS Pharmaceutics Ltd. Announces Notice of Allowance of a New Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy
Press release content from PR Newswire. The AP news staff was not involved in its creation. NLS Pharmaceutics Ltd. Announces Notice of Allowance of a New Technology Patent Covering Attention Deficit Hyperactivity Disorder & Narcolepsy January 21, 2021 GMT STANS, Switzerland, Jan. 21, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NLS), a Swiss biotech firm focusing on the development of novel treatments of rare neurological diseases including narcolepsy, idiopathic hypersomnia and Kleine-Levin Sy...
Alex Zwyer European Patent Office Canadian Intellectual Property Office Pharmaceutics Ltd Kleine Levin Syndrome Attention Deficit Hyperactivity Disorder
Source: apnews.com